Fig. 6From: Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitorsPseudoprogression in a patient with HCC under Nivolumab and Lenvatinib. Discordant elevation of AFP at PsPD is shown. Red arrows indicate the tumor burden at a specific time point. AFP alpha feto protein, HCC hepatocellular carcinomaBack to article page